artificial intelligence
The company behind the patient-facing app just inked a deal with Labcorp to educate patients around biomarker testing including for HER2-low breast cancer.
BostonGene, Hokkaido University to Study Biomarkers of Response in HER2-Positive Breast Cancer
The collaborators aim to use BostonGene's algorithms and genomics tools to identify HER2-positive breast cancer patients likely to respond to certain therapies.
DoMore Diagnostics, Proscia Ink Collaboration on Colorectal Cancer Histopathology Testing
The digital pathology firms will combine their technologies to help pathologists predict patient outcomes and incorporate AI-supported decision-making.
The test uses a deep learning model to evaluate features of tumor cells and clinical variables and predict the risk of breast cancer recurrence.
Renovaro Biosciences, GEDi Cube Announce Intent to Merge, Develop Precision Oncology Drugs
The companies want to join forces and use GEDi's AI platform to home in on cancers most likely to respond to treatments Renovaro is developing.